Answers are grounded in this paper and cite their sources.
Background and Aims Terlipressin improves renal function in about 40% of patients with hepatorenal syndrome–acute kidney injury (HRS-AKI). Nonetheless, terlipressin's pathophysiological mechanisms remain unclear. Therefore, we investigated the cardiovascular changes that occur after terlipressin is given to patients with HRS-AKI. Methods Cardiac and phase-contrast magnetic resonance imaging (MRI) were used to assess cardiac function, as well as renal, splanchnic, and peripheral blood flow changes after the first bolus of 2 mg terlipressin in ten patients with HRS-AKI, six of whom also had acute-on-chronic liver failure. Hemodynamic changes were analyzed using the Wilcoxon matched-pairs signed-rank test. Patients were followed prospectively to investigate any associations between terlipressin-induced hemodynamic changes and clinical outcomes. Results Cardiac output (CO) decreased by 15% following terlipressin (p < 0.01). Despite this decrease in CO, renal artery blood flow increased by 23% (p < 0.01), and the renal artery blood flow percentage of CO increased by 49% (p = 0.01). Superior mesenteric artery blood flow and femoral artery blood flow decreased by 27% and 40%, respectively (both p < 0.01). Mean arterial pressure (MAP) and systemic vascular resistance increased by 13% and 32%, respectively (both p < 0.01). Baseline renal artery blood flow correlated with serum creatinine (p < 0.01). In contrast, changes in renal artery blood flow and other cardiocirculatory variables did not correlate with changes in serum creatinine after terlipressin, nor with mortality. Conclusions Terlipressin increases renal artery blood flow, reduces CO, and alleviates splanchnic and peripheral vasodilatation. These effects, combined with an increase in MAP, seem to explain the therapeutic benefits of terlipressin in patients with HRS-AKI. Clinical.trials.gov registration ID: NCT03483272 Impact and Implications This study is the first to provide a detailed mapping of the hemodynamic changes following terlipressin in critically ill patients with HRS-AKI. The results indicate that terlipressin's beneficial effects are driven by selective peripheral and splanchnic vasoconstriction, which redistributes blood flow, normalizes mean arterial pressure, and ultimately improves renal perfusion despite reduced cardiac output. This study also highlights the advantages of using magnetic resonance imaging as a non-invasive method to evaluate pharmacological interventions, with the potential to contribute to future advancements in personalized medicine for patients with cirrhosis.
No takes yet. Share an insight, caveat, or question.
Danielsen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: